Lieu et al. measured levels of PlGF, VEGF-A, VEGF-C and VEGF-D in sequential plasma samples of metastatic CRC patients treated with chemotherapy plus bevacizumab, and of control cohorts subjected to regimens with or without bevacizumab [160]. This evidence concerns the gene PGF and colorectal carcinoma.